New drug regimen speeds TB treatment
Publish Date: Jul 21, 2014
New drug regimen speeds TB treatment
  • mail
  • img

An experimental cocktail of three drugs can dramatically shorten the time it takes to treat patients infected with TB strains that are hard to cure with conventional antibiotics, according to research presented Monday at the world AIDS forum.

Dubbed the PaMZ regimen, the drugs killed more TB bacteria than standard therapy and at a faster rate in a so-called Phase IIb trial, usually the penultimate step in vetting new treatments for safety and effectiveness, investigators said.

If funding is found, PaMZ will move to Phase III tests by the end of the year, their backers, TB Alliance, said.

Doctors are deeply worried by the emergence of tuberculosis bacteria that fail to respond to frontline antibiotics.

These resistant strains are especially dangerous for people co-infected with the human immunodeficiency virus (HIV), which causes AIDS. HIV attacks CD4 immune cells, leaving the body exposed to opportunistic microbes.

PaMZ comprises two candidate drugs that are not yet licensed for use against TB, called Pa-824 and moxifloxacin, deployed with an existing treatment, pyrazinamide.

The treatment, which is administered as tablets, was formulated specifically for patients believed to have TB strains that can be targeted by these drugs.

The trial reported at the 20th International AIDS Conference in Melbourne entailed testing PaMZ against standard drugs -- isoniazid, rifampicin, pyrazinamide and ethambutol -- among 207 volunteers in South Africa, a fifth of whom were co-infected with HIV.

Of these, 181 were sensitive to the PaMZ drugs while 26 were multidrug-resistant (MDR), meaning that they had failed to respond to conventional antibiotics.

It found that 71 percent of people treated with PaMZ were cleared of TB bacteria in their sputum within two months. By comparison, only 38 percent of those on standard therapy were clear at eight weeks.

The MDR patients all took PaMZ and were treated within four to six months, compared to two years for standard treatment. This should translate into cost savings of more than 90 percent in some countries, as MDR therapy is complex and labour-intensive.

Another boon was that PaMZ showed no signs of interfering with commonly-used antiretrovial treatments to suppress HIV.

"TB remains the largest killer of people with AIDS, causing one in five HIV-related deaths globally. Yet often TB and HIV therapies cannot be given together because of side effects, making it difficult to treat both diseases simultaneously," TB Alliance said.

At least a third of the roughly 35 million people living within HIV worldwide are infected with TB in its latent form, meaning that they have the Mycobacterium tuberculosis germ that causes the disease but do not yet have any symptoms of illness, according to the UN's World Health Organization (WHO).AFP/PHOTO


The statements, comments, or opinions expressed through the use of New Vision Online are those of their respective authors, who are solely responsible for them, and do not necessarily represent the views held by the staff and management of New Vision Online.

New Vision Online reserves the right to moderate, publish or delete a post without warning or consultation with the author.Find out why we moderate comments. For any questions please contact

  • mail
  • img
blog comments powered by Disqus
Also In This Section
KCCA set for tough Champions Cup
THE KCCA Leopards are honest enough to admit it will be difficult to make it out of the group stages of the 2015 FIBA Women’s Africa Champions Cup...
Inflation rises to 9.1% in November
The Annual inflation for November 2015 rose to 9.1% compared to 8.8% for October. According to Uganda Bureau of Statistics figures released on Monday in Kampala, the monthly core inflation for November 2015 accelerated by 0.5% from 0.1% for October 2015....
Crowds are deceptive, candidates told
TRANSPARENCY International has warned presidential candidates not to be misled by the big crowds turning up for their campaign rallies because a big number of them are not their supporters...
NRM endorses Tindyebwa for Rubaga North
THE NRM Electoral Commission has endorsed Brian Tindyebwa as the party''s flag bearer for the Lubaga North Parliamentary seat in the forthcoming 2016 elections...
Amama Mbabazi halts campaigns
PRESIDENTIAL candidate Amama Mbabazi has halted his campaign program for one week after flying to the United Kingdom to visit his wife Jacqueline Mbabazi...
Kadaga bars MPs from facing UNRA probe
SPEAKER of parliament, Rebecca Kadaga, has put an end to a possibility of any lawmaker appearing before the ongoing probe into mismanagement of funds at Uganda National Roads Authority...
Do you think Uganda is winning the fight against AIDS?
Can't Say
follow us
subscribe to our news letter